{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:36:31Z","timestamp":1793108191402,"version":"4.5.0"},"reference-count":156,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010733","name":"B\u00f8rnecancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ejmg.2023.104869","type":"journal-article","created":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:47:41Z","timestamp":1698540461000},"page":"104869","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX\/MEIS1 expression"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-8115","authenticated-orcid":false,"given":"Kristian L.","family":"Juul-Dam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neerav N.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Branko","family":"Cuglievan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Anders","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Rasouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hasle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmg.2023.104869_bib1","series-title":"ACCELERATE Virtual Meeting on Menin Inhibitors","year":"2022"},{"key":"10.1016\/j.ejmg.2023.104869_bib2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","article-title":"Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance","volume":"106","author":"Alcalay","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib3","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1200\/JCO.2016.67.5066","article-title":"Phase I study of selinexor, a selective inhibitor of nuclear export, in combination with fludarabine and cytarabine, in pediatric relapsed or refractory acute leukemia","volume":"34","author":"Alexander","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib4","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1002\/cncr.30791","article-title":"Decreased relapsed rate and treatment\u2010related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials","volume":"123","author":"Alexander","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejmg.2023.104869_bib5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2011.133","article-title":"IDH1 and IDH2 mutations in pediatric acute leukemia","volume":"25","author":"Andersson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmg.2023.104869_bib7","first-page":"95","article-title":"LEDGF\/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis","volume":"131","author":"Ashkar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib8","first-page":"595","article-title":"IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia","volume":"3","author":"Aubrey","year":"2022","journal-title":"Nat. Can. (Ott.)"},{"key":"10.1016\/j.ejmg.2023.104869_bib9","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2009-04-216606","article-title":"Leukemogenic transformation by HOXA cluster genes","volume":"115","author":"Bach","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib10","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","article-title":"The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia","volume":"76","author":"Baker","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmg.2023.104869_bib11","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3324\/haematol.2010.038976","article-title":"Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia","volume":"96","author":"Balgobind","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2023.104869_bib13","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.3324\/haematol.2014.116574","article-title":"Late cardiomyopathy in childhood acute myeloid leukemia survivors: a study from the L.E.A. program","volume":"100","author":"Barlogis","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2023.104869_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/leu.2011.31","article-title":"Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group","volume":"25","author":"Berman","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2011.06.010","article-title":"MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L","volume":"20","author":"Bernt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib16","doi-asserted-by":"crossref","first-page":"997.e1","DOI":"10.1016\/j.jtct.2021.09.005","article-title":"Hypomethylating agents and FLT3 inhibitors as maintenance treatment for acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation\u2013A systematic review and meta-analysis","volume":"27","author":"Bewersdorf","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.ejmg.2023.104869_bib17","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/s41375-021-01134-3","article-title":"Late outcomes in survivors of childhood acute myeloid leukemia: a report from the st. Jude lifetime cohort study","volume":"35","author":"Bhatt","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib18","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/leu.2016.361","article-title":"NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group","volume":"31","author":"Bisio","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmg.2023.104869_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1182\/blood-2007-02-076604","article-title":"The incidence and clinical significance of nucleophosmin mutations in childhood AML","volume":"110","author":"Brown","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib22","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib23","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.2021011917","article-title":"Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib24","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","article-title":"Interaction of MLL amino terminal sequences with menin is required for transformation","volume":"67","author":"Caslini","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmg.2023.104869_bib25","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood-2005-03-0899","article-title":"Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype","volume":"106","author":"Cazzaniga","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41420-021-00496-y","article-title":"Interrogation of novel CDK2\/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML","volume":"7","author":"Chantkran","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmg.2023.104869_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1073\/pnas.0510347103","article-title":"The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression","volume":"103","author":"Chen","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmg.2023.104869_bib28","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1158\/0008-5472.CAN-07-6514","article-title":"Loss of MLL PHD finger 3 is necessary for MLL-ENL\u2013induced hematopoietic stem cell immortalization","volume":"68","author":"Chen","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmg.2023.104869_bib29","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmg.2023.104869_bib30","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2004.01.191","article-title":"Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98","volume":"22","author":"Creutzig","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","article-title":"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004","volume":"122","author":"Creutzig","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib32","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1002\/cncr.30220","article-title":"Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups","volume":"122","author":"Creutzig","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejmg.2023.104869_bib33","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/leu.2016.327","article-title":"Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia","volume":"31","author":"Dafflon","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ccr.2011.06.009","article-title":"Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor","volume":"20","author":"Daigle","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/blood-2013-04-497644","article-title":"Potent inhibition of DOT1L as treatment of MLL-fusion leukemia","volume":"122","author":"Daigle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib36","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmg.2023.104869_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/leu.2013.338","article-title":"Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia","volume":"28","author":"Dawson","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib38","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib39","series-title":"Update on a Phase 1\/2 First-In-Human Study of the Menin-Kmt2a (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia","author":"Erba","year":"2022"},{"key":"10.1016\/j.ejmg.2023.104869_bib40","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2023.104869_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/blood-2002-10-3221","article-title":"Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation","volume":"102","author":"Ferrando","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmg.2023.104869_bib43","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib44","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1083\/jcb.144.6.1097","article-title":"A conserved biogenesis pathway for nucleoporins: proteolytic processing of a 186-kilodalton precursor generates Nup98 and the novel nucleoporin, Nup96","volume":"144","author":"Fontoura","year":"1999","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234103","article-title":"Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer","volume":"15","author":"Frame","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmg.2023.104869_bib46","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1101\/gad.306753.117","article-title":"Nup98 recruits the Wdr82\u2013Set1A\/COMPASS complex to promoters to regulate H3K4 trimethylation in hematopoietic progenitor cells","volume":"31","author":"Franks","year":"2017","journal-title":"Gene Dev."},{"key":"10.1016\/j.ejmg.2023.104869_bib47","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children's Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib48","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib49","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood.V84.11.3637.bloodjournal84113637","article-title":"Key functional role and lineage-specific expression of selected HOXB genes in purified hematopoietic progenitor differentiation","volume":"84","author":"Giampaolo","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1091\/mbc.e02-09-0582","article-title":"Nup98 localizes to both nuclear and cytoplasmic sides of the nuclear pore and binds to two distinct nucleoporin subcomplexes","volume":"14","author":"Griffis","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib52","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1172\/JCI97117","article-title":"Leukemogenic nucleophosmin mutation disrupts the transcription factor hub regulating granulo-monocytic fates","volume":"128","author":"Gu","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmg.2023.104869_bib53","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1073\/pnas.0503072102","article-title":"Global and Hox-specific roles for the MLL1 methyltransferase","volume":"102","author":"Guenther","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmg.2023.104869_bib54","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib55","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2012-03-416701","article-title":"Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004","volume":"120","author":"Hasle","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib56","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/leu.2015.144","article-title":"Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner","volume":"30","author":"He","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib57","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib58","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.emboj.7600038","article-title":"Hematopoietic, angiogenic and eye defects in Meis1 mutant animals","volume":"23","author":"Hisa","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmg.2023.104869_bib59","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/leu.2008.313","article-title":"Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML","volume":"23","author":"Hollink","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib60","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1182\/blood-2011-04-346643","article-title":"NUP98\/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern","volume":"118","author":"Hollink","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib61","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/s41589-020-0626-6","article-title":"Covalent inhibition of NSD1 histone methyltransferase","volume":"16","author":"Huang","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib62","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1097-2765(04)00081-4","article-title":"Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus","volume":"13","author":"Hughes","year":"2004","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmg.2023.104869_bib63","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbrc.2021.12.078","article-title":"CN470 is a BET\/CBP\/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia","volume":"590","author":"Imayoshi","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmg.2023.104869_bib64","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib65","series-title":"Outcomes after Transplant in Relapsed\/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) Leukemia Patients Achieving Remissions after Menin Inhibition: Revumenib (SNDX-5613) Ph1 Experience","author":"Issa","year":"2022"},{"key":"10.1016\/j.ejmg.2023.104869_bib66","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ejmg.2023.104869_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/ejh.12683","article-title":"Cardiac function in survivors of childhood acute myeloid leukemia treated with chemotherapy only: a NOPHO\u2010AML study","volume":"97","author":"Jarfelt","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ejmg.2023.104869_bib68","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/nature04221","article-title":"The Rae1\u2013Nup98 complex prevents aneuploidy by inhibiting securin degradation","volume":"438","author":"Jeganathan","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ejmg.2023.104869_bib69","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bjh.14720","article-title":"Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia","volume":"178","author":"Karlsson","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmg.2023.104869_bib70","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1128\/MCB.19.1.764","article-title":"CREB binding protein interacts with nucleoporin-specific FG repeats that activate transcription and mediate NUP98-HOXA9 oncogenicity","volume":"19","author":"Kasper","year":"1999","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.leu.2401410","article-title":"Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells","volume":"13","author":"Kawagoe","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28099","article-title":"Causes of early death and treatment\u2010related death in newly diagnosed pediatric acute myeloid leukemia: recent experiences of the Dutch Childhood Oncology Group","volume":"67","author":"Klein","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejmg.2023.104869_bib73","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmg.2023.104869_bib74","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.13949","article-title":"Hoxa10 null animals exhibit reduced platelet biogenesis","volume":"173","author":"Konieczna","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmg.2023.104869_bib75","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib76","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmg.2023.104869_bib77","series-title":"Press Release: Kura Oncology Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia","year":"2022"},{"key":"10.1016\/j.ejmg.2023.104869_bib78","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/ng.3371","article-title":"The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias","volume":"47","author":"Lavall\u00e9e","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmg.2023.104869_bib79","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.V89.6.1922","article-title":"Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis","volume":"89","author":"Lawrence","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib80","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","article-title":"AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia","volume":"37","author":"Lin","year":"2010","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmg.2023.104869_bib81","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3324\/haematol.2016.146175","article-title":"Effect of age and body weight on toxicity and survival in pediatric acute myeloid leukemia: results from NOPHO-AML 2004","volume":"101","author":"L\u00f8hmann","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2023.104869_bib82","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/leu.2013.10","article-title":"Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF\/p75)","volume":"27","author":"M\u00e9reau","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib84","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib85","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.0503630102","article-title":"MLL associates specifically with a subset of transcriptionally active target genes","volume":"102","author":"Milne","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmg.2023.104869_bib86","series-title":"Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer","author":"Mitelman","year":"2022"},{"key":"10.1016\/j.ejmg.2023.104869_bib87","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1365-2141.2010.08554.x","article-title":"Treatment-related deaths in second complete remission in childhood acute myeloid leukaemia","volume":"152","author":"Molgaard-Hansen","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmg.2023.104869_bib88","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.leu.2404808","article-title":"Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias","volume":"21","author":"Mullighan","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib89","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1002\/cncr.23405","article-title":"Twenty years of follow\u2010up among survivors of childhood and young adult acute myeloid leukemia","volume":"112","author":"Mulrooney","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejmg.2023.104869_bib90","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ccr.2010.04.012","article-title":"The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis","volume":"17","author":"Muntean","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib91","doi-asserted-by":"crossref","first-page":"31742","DOI":"10.1074\/jbc.M111.258186","article-title":"Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein","volume":"286","author":"Murai","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmg.2023.104869_bib92","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1182\/blood-2014-01-550079","article-title":"The same site on the integrase-binding domain of lens epithelium\u2013derived growth factor is a therapeutic target for MLL leukemia and HIV","volume":"124","author":"Murai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib93","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1200\/JCO.2009.25.6321","article-title":"Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98","volume":"28","author":"Neuhoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib94","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1609128","article-title":"Mutated WT1, FLT3-ITD, and NUP98-NSD1 fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia","author":"Niktoreh","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib95","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3324\/haematol.2019.236745","article-title":"The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia","volume":"106","author":"Noort","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2023.104869_bib96","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2012.08.001","article-title":"Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes","volume":"40","author":"Novak","year":"2012","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmg.2023.104869_bib97","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cell.2011.01.004","article-title":"Densely interconnected transcriptional circuits control cell states in human hematopoiesis","volume":"144","author":"Novershtern","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib98","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cell.2005.02.020","article-title":"hDOT1L links histone methylation to leukemogenesis","volume":"121","author":"Okada","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib99","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1172\/JCI91406","article-title":"Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia","volume":"127","author":"Okuda","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmg.2023.104869_bib100","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2023.104869_bib101","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2020.04.038","article-title":"Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents","volume":"136","author":"Pearson","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmg.2023.104869_bib102","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed\/refractory acute myeloid leukemia: a multicenter, first-in-human, open-label, phase 1\/2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib103","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1182\/bloodadvances.2022007563","article-title":"Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML","volume":"6","author":"Pianigiani","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmg.2023.104869_bib104","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1158\/0008-5472.CAN-15-0236","article-title":"Generation of a selective small molecule inhibitor of the CBP\/p300 bromodomain for leukemia therapy","volume":"75","author":"Picaud","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmg.2023.104869_bib105","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 Year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib106","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0301-472X(01)00757-3","article-title":"Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny","volume":"30","author":"Pineault","year":"2002","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ejmg.2023.104869_bib107","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1091\/mbc.e13-12-0717","article-title":"Nucleophosmin modulates stability, activity, and nucleolar accumulation of base excision repair proteins","volume":"25","author":"Poletto","year":"2014","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib108","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III children's Oncology group trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib109","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the children's Oncology group protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib110","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199112123252402","article-title":"Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia","volume":"325","author":"Pui","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2023.104869_bib111","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/pbc.24464","article-title":"Epidemiology of childhood acute myeloid leukemia","volume":"60","author":"Puumala","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejmg.2023.104869_bib112","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0092-8674(95)90331-3","article-title":"The peptide repeat domain of nucleoporin Nup98 functions as a docking site in transport across the nuclear pore complex","volume":"81","author":"Radu","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib113","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-15-2885","article-title":"XPO1 inhibition using selinexor synergizes with chemotherapy in acute myeloid leukemia by targeting DNA repair and restoring topoisomerase II\u03b1 to the nucleus","volume":"22","author":"Ranganathan","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmg.2023.104869_bib114","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1038\/s41375-018-0071-7","article-title":"Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012","volume":"32","author":"Rasche","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib115","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.3390\/cancers13102336","article-title":"Survival following relapse in children with acute myeloid leukemia: a report from AML-BFM and COG","volume":"13","author":"Rasche","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmg.2023.104869_bib116","first-page":"150","article-title":"NUP98\/NSD1-Positive AML is addicted to a functional menin-MLL interaction","volume":"5","author":"Rasouli","year":"2021","journal-title":"HemaSphere"},{"key":"10.1016\/j.ejmg.2023.104869_bib117","doi-asserted-by":"crossref","first-page":"10406","DOI":"10.1073\/pnas.1005389107","article-title":"Structural and functional analysis of the interaction between the nucleoporin Nup98 and the mRNA export factor Rae1","volume":"107","author":"Ren","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmg.2023.104869_bib118","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125943","article-title":"Structural variants involving MLLT10\/AF10 are associated with adverse outcome in AML regardless of the partner gene - a COG\/tpaml study","volume":"134","author":"Ries","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib119","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/leu.2017.194","article-title":"The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia","volume":"31","author":"Rio-Machin","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib120","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2013.87","article-title":"NUP98\/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern","volume":"27","author":"Rooij","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib121","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1200\/JCO.2002.08.023","article-title":"Favorable impact of the t(9;11) in childhood acute myeloid leukemia","volume":"20","author":"Rubnitz","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib122","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmg.2023.104869_bib123","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2013.098517","article-title":"t(6;9)(p22;q34)\/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients","volume":"99","author":"Sandahl","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2023.104869_bib124","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.1073\/pnas.91.25.12223","article-title":"Differential expression of homeobox genes in functionally distinct CD34+ subpopulations of human bone marrow cells","volume":"91","author":"Sauvageau","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmg.2023.104869_bib125","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/s41375-019-0382-3","article-title":"CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex","volume":"33","author":"Schmidt","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib156","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41467-021-21255-8","article-title":"The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms","volume":"12","author":"Schwartz","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmg.2023.104869_bib126","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4252\/wjsc.v7.i3.583","article-title":"Role of Hox genes in stem cell differentiation","volume":"7","author":"Seifert","year":"2015","journal-title":"World J. Stem Cell."},{"key":"10.1016\/j.ejmg.2023.104869_bib127","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/leu.2017.62","article-title":"MLL is essential for NUP98-HOXA9-induced leukemia","volume":"31","author":"Shima","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib128","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/jnci\/djz016","article-title":"Long-term risk of hospitalization among five-year survivors of childhood leukemia in the nordic countries","volume":"111","author":"S\u00f8rensen","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmg.2023.104869_bib129","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/leu.2015.6","article-title":"Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells","volume":"29","author":"Spencer","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib130","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1182\/bloodadvances.2020001879","article-title":"Antitumor activity of the dual BET and CBP\/EP300 inhibitor NEO2734","volume":"4","author":"Spriano","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmg.2023.104869_bib131","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib132","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2023.104869_bib133","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/leu.2016.267","article-title":"NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis","volume":"31","author":"Struski","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2023.104869_bib134","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/1078-0432.CCR-19-2169","article-title":"Phase I clinical trial of selinexor in combination with daunorubicin and cytarabine in previously untreated poor-risk acute myeloid leukemia","volume":"26","author":"Sweet","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmg.2023.104869_bib135","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127569","article-title":"Response to sorafenib in FLT3\/ITD AML is depedent on Co-occurring mutational profile","volume":"134","author":"Tarlock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2023.104869_bib136","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2023.104869_bib137","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/MCB.17.1.495","article-title":"Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia","volume":"17","author":"Thorsteinsdottir","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib138","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1128\/MCB.21.1.224-234.2001","article-title":"Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia","volume":"21","author":"Thorsteinsdottir","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib139","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmg.2023.104869_bib140","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmg.2023.104869_bib141","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1038\/onc.2013.251","article-title":"Functional regulation of the apurinic\/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology","volume":"33","author":"Vascotto","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmg.2023.104869_bib142","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/ncb1608","article-title":"NUP98\u2013NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis","volume":"9","author":"Wang","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib143","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nature08036","article-title":"Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger","volume":"459","author":"Wang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmg.2023.104869_bib144","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hub to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmg.2023.104869_bib145","article-title":"Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A -rearranged acute myeloid leukemia: a study by the international berlin-frankfurt-m\u00fcnster study group","author":"Weelderen","year":"2023","journal-title":"J Clin Oncol JCO2202120"},{"key":"10.1016\/j.ejmg.2023.104869_bib146","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ccell.2016.10.019","article-title":"NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis","volume":"30","author":"Xu","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/celldisc.2016.8","article-title":"MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program","volume":"2","author":"Xu","year":"2016","journal-title":"Cell Discov"},{"key":"10.1016\/j.ejmg.2023.104869_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-019-0268-7","article-title":"Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia","volume":"10","author":"Xu","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ejmg.2023.104869_bib149","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccr.2008.05.003","article-title":"Menin critically links MLL proteins with LEDGF on cancer-associated target genes","volume":"14","author":"Yokoyama","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.ejmg.2023.104869_bib151","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1128\/MCB.26.10.3798-3809.2006","article-title":"Nucleophosmin is essential for ribosomal protein L5 nuclear export","volume":"26","author":"Yu","year":"2006","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmg.2023.104869_bib152","doi-asserted-by":"crossref","first-page":"10610","DOI":"10.1073\/pnas.91.22.10610","article-title":"11q23 translocations split the \u201cAT-hook\u201d cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene","volume":"91","author":"Zeleznik-Le","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmg.2023.104869_bib153","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3324\/haematol.2017.185082","article-title":"Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial","volume":"103","author":"Zhang","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2023.104869_bib154","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/2159-8290.CD-16-0058","article-title":"ASH1L links histone H3 lysine 36 dimethylation to MLL leukemia","volume":"6","author":"Zhu","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmg.2023.104869_bib155","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721223001751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721223001751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:54:37Z","timestamp":1761710077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721223001751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":156,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1769721223001751"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2023.104869","relation":{},"ISSN":["1769-7212"],"issn-type":[{"value":"1769-7212","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX\/MEIS1 expression","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2023.104869","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104869"}}